Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations
Our study underscores the critical role of MTBs in optimizing clinical outcomes for patients with advanced cancer through precise identification of actionable molecular alterations. Our findings highlight the necessity of incorporating ESCAT II and III alterations into precision medicine frameworks to expand therapeutic opportunities and the importance of earlier targeting of driver alterations.
Authors
- M. Huerta
- Juan Miguel Cejalvo (ORCID: https://orcid.org/0000-0002-8755-8626)
- Paloma Martín-Martorell (ORCID: https://orcid.org/0000-0002-6728-8366)
- Juan Antonio Carbonell‐Asins (ORCID: https://orcid.org/0000-0002-8449-5674)
- Alba Viala
- Amelia Insa (ORCID: https://orcid.org/0000-0002-3438-6170)
- J. Martín-Arana
- Marta Tapia (ORCID: https://orcid.org/0000-0002-0266-1289)
- Valentina Gambardella (ORCID: https://orcid.org/0000-0001-6081-8830)
- G. Bruixola (ORCID: https://orcid.org/0000-0003-3229-0770)
- Tania Fleitas (ORCID: https://orcid.org/0000-0002-2789-9082)
- A. Cervantes
- Inés González‐Barrallo (ORCID: https://orcid.org/0000-0002-9154-338X)
- Desamparados Roda (ORCID: https://orcid.org/0000-0003-2657-9623)
- Carolina Martínez‐Ciarpaglini (ORCID: https://orcid.org/0000-0002-8797-2114)
- N. Grimalt
- Víctor Seguí
- M. García-Bartolomé
- José González (ORCID: https://orcid.org/0000-0002-9832-3355)
- N. Tarazona
Institutions
- INCLIVA Health Research Institute (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105771
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52